Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy

BACKGROUND: For patients with melanoma, gastrointestinal immune-related adverse events are common after receipt of anti-CTLA4 therapy. These present difficult decision points regarding whether to discontinue therapy. Detailing the situations in which colitis might predict for improved survival and h...

Descripción completa

Detalles Bibliográficos
Autores principales: Anstadt, Emily J, Chu, Brian, Yegya-Raman, Nikhil, Han, Xiaoyan, Doucette, Abigail, Poirier, Kendra, Mohiuddin, Jahan J, Maity, Amit, Facciabene, Andrea, Amaravadi, Ravi K, Karakousis, Giorgos C, Cohen, Justine V, Mitchell, Tara C, Schuchter, Lynn M, Lukens, John N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Melanoma and Cutaneous Malignancies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438915/
https://www.ncbi.nlm.nih.gov/pubmed/35666292
http://dx.doi.org/10.1093/oncolo/oyac108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438915/
https://www.ncbi.nlm.nih.gov/pubmed/35666292
http://dx.doi.org/10.1093/oncolo/oyac108

Ejemplares similares